Subcutaneous infusion of bleomycin--a practical alternative to intravenous infusion.
The phase specificity and short half-life of bleomycin make it likely that it would be more effective when administered by continuous infusion. This is supported by studies using cell lines, as well as by animal studies and clinical experience in humans. This study was conducted to compare the pharmacokinetics of intravenous (IV) and subcutaneous infusions of bleomycin. The serum concentrations of bleomycin were measured using a sensitive and specific radioimmunoassay. The results demonstrate similar plasma concentrations and area under the curve for both routes. The subcutaneous infusions were well tolerated, without local discomfort or excoriation. Subcutaneous infusion of bleomycin may thus offer a practical alternative to IV infusions and can be administered to patients who are ambulatory and out of hospital.
D001761:Bleomycin / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D005260:Female; D005833:Genital Neoplasms, Female / Q000378:metabolism; D005834:Genital Neoplasms, Male / Q000378:metabolism; D006258:Head and Neck Neoplasms / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007700:Kinetics; D008297:Male
D001761:Bleomycin